VisEn Medical, a developer of fluorescence in vivo imaging, has commercially launched its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis.

The Bedford, Mass.-based company said its new Annexin-Vivo 750 agent is based on the Annexin labeling standard within in vitro research. Also, VisEn hopes it will expand research areas and drug development by enabling real-time imaging of apoptosis biomarkers associated with disease progression and therapeutic response.

Annexin-Vivo 750 targets membrane-bound phosphatidylserine exposed in the outer leaflet of the plasma membrane during the induction of apoptosis, VisEn said.